ticagrelor + clopidogrel

ApprovedTerminated
0 watching 0 views this week๐Ÿ”ฅ Hot
85
Hype Score

Development Stage

โœ“
Pre-clinical
โœ“
Phase 1
โœ“
Phase 2
โœ“
Phase 3
5
Approved
Indication / Disease

Non-ST Elevation Acute Coronary Syndrome

Conditions

Non-ST Elevation Acute Coronary Syndrome

Trial Timeline

Sep 1, 2014 โ†’ Apr 1, 2015

About ticagrelor + clopidogrel

ticagrelor + clopidogrel is a approved stage product being developed by AstraZeneca for Non-ST Elevation Acute Coronary Syndrome. The current trial status is terminated. This product is registered under clinical trial identifier NCT02052635. Target conditions include Non-ST Elevation Acute Coronary Syndrome.

Hype Score Breakdown

Clinical
30
Activity
20
Company
10
Novelty
10
Community
12

Clinical Trials (20)

NCT IDPhaseStatus
NCT04069234Phase 3Withdrawn
NCT03437044ApprovedCompleted
NCT02617290Phase 3Completed
NCT02663713ApprovedCompleted
NCT02319941Phase 2Completed
NCT02457130ApprovedUNKNOWN
NCT02379676ApprovedUNKNOWN
NCT02121288ApprovedWithdrawn
NCT02233790ApprovedUNKNOWN
NCT02618733Pre-clinicalCompleted
NCT02052635ApprovedTerminated
NCT01826175ApprovedWithdrawn
NCT01864005ApprovedCompleted
NCT01732822Phase 3Completed
NCT01706510ApprovedCompleted
NCT01603082ApprovedCompleted
NCT01523366ApprovedCompleted
NCT01523392ApprovedCompleted
NCT01118325Phase 2Completed
NCT00391872Phase 3Completed

Competing Products

2 competing products in Non-ST Elevation Acute Coronary Syndrome

See all competitors
ProductCompanyStageHype Score
Tirofiban + TicagrelorAstraZenecaPhase 3
77
Ticagrelor + ClopidogrelAstraZenecaApproved
85